OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Efficacy and safety of alectinib in ALK-positive non-small cell lung cancer and blood markers for prognosis and efficacy: a retrospective cohort study
Yingying Jiang, Yue Shi, Yiling Liu, et al.
Translational Lung Cancer Research (2022) Vol. 11, Iss. 12, pp. 2521-2538
Open Access | Times Cited: 6
Yingying Jiang, Yue Shi, Yiling Liu, et al.
Translational Lung Cancer Research (2022) Vol. 11, Iss. 12, pp. 2521-2538
Open Access | Times Cited: 6
Showing 6 citing articles:
Unraveling the unforeseen: anuric acute kidney injury induced by alectinib
Viet Nghi Tran, Yusuf Hussein Kebato, Chau Nguyen, et al.
Hospital Practice (2025)
Closed Access
Viet Nghi Tran, Yusuf Hussein Kebato, Chau Nguyen, et al.
Hospital Practice (2025)
Closed Access
Preoperative evaluation and a nomogram prediction model for pelvic lymph node metastasis in endometrial cancer
Jie Zhang, Dengfeng Wang, Liping Peng, et al.
European Journal of Surgical Oncology (2024) Vol. 50, Iss. 4, pp. 108230-108230
Closed Access | Times Cited: 3
Jie Zhang, Dengfeng Wang, Liping Peng, et al.
European Journal of Surgical Oncology (2024) Vol. 50, Iss. 4, pp. 108230-108230
Closed Access | Times Cited: 3
Evaluation of Solubility, Dissolution Rate, and Oral Bioavailability of β-Cyclodextrin and Hydroxypropyl β-Cyclodextrin as Inclusion Complexes of the Tyrosine Kinase Inhibitor, Alectinib
Bashar J. M. Majeed, Mohammed A. Saadallah, Israa Al‐Ani, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 6, pp. 737-737
Open Access | Times Cited: 3
Bashar J. M. Majeed, Mohammed A. Saadallah, Israa Al‐Ani, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 6, pp. 737-737
Open Access | Times Cited: 3
Tailoring Therapeutic Strategies in Non-Small-Cell Lung Cancer: The Role of Genetic Mutations and Programmed Death Ligand-1 Expression in Survival Outcomes
Nobuaki Kobayashi, Kenji Miura, Ayami Kaneko, et al.
Cancers (2023) Vol. 15, Iss. 21, pp. 5248-5248
Open Access | Times Cited: 3
Nobuaki Kobayashi, Kenji Miura, Ayami Kaneko, et al.
Cancers (2023) Vol. 15, Iss. 21, pp. 5248-5248
Open Access | Times Cited: 3
Clinicopathological characteristics correlated with programmed cell death-ligand 1 expression in advanced lung adenocarcinoma
Hengxing Gao, Xuexue Zou, Jing Wang, et al.
Journal of Thoracic Disease (2023) Vol. 15, Iss. 10, pp. 5307-5318
Open Access
Hengxing Gao, Xuexue Zou, Jing Wang, et al.
Journal of Thoracic Disease (2023) Vol. 15, Iss. 10, pp. 5307-5318
Open Access
